SILVER SPRING, Md.--(BUSINESS WIRE)-- Nuvilex, Inc. (OTCQB:NVLX) announced its treatment approach for solid tumors in pancreatic cancer, designed by Nuvilex’s acquired company SG Austria, has been endorsed in recent scientific reviews published in the medical literature. These review articles focused on suicide genes and corresponding prodrug conversions for the treatment of various forms of cancer, and featured the value of the Company’s approach to treat pancreatic cancer.
The pancreatic cancer treatment recently restarted by Nuvilex and SG Austria in preparation for clinical trials utilizes encapsulated living cells that overexpress the cytochrome P450 gene that converts prodrugs into their active counterparts. These encapsulated cells are implanted near the tumor and low dose ifosfamide chemotherapy is then given to the patient. The ongoing preparations being carried out by Nuvilex for the next pancreatic clinical trial will utilize this same method, cell type, and chemotherapy mechanism in order to maintain the clarity of the trial design and potential patient benefits.
The new medical reviews which appeared in recent issues of the publications Cancers and Molecular Pharmacology Fast Forward, described the approach, design, and methodology as encouraging, both with respect to safety and efficacy in the absence of typical adverse chemotherapeutic side effects. Nuvilex and SG Austria are currently on track to start these trials in 2012.
"We are pleased the encapsulated cell therapy being developed is being recognized by the scientific and medical community," said Dr. Robert F. Ryan. "The original Lancet paper describing the first trials of the encapsulated cell therapy for pancreatic cancer has been cited over 100 times. Our ultimate goal is to develop a treatment that provides substantial relief for the 250,000 patients worldwide with newly diagnosed pancreatic cancer.”
Nuvilex, Inc. (OTCQB: NVLX) is an innovative biotechnology and natural products company whose oncology offerings include cancer treatment using the company’s industry-leading live-cell encapsulation technology. Current natural products include flagship Gluten-Free Cinnergen™ and others to enhance a healthy lifestyle, cosmetic use, flu treatment, tattoo inks, antimicrobial and antinematodal agents.
Safe Harbor Statement
This information may contain forward-looking statements and involve risks and uncertainties. Results, events and performances could vary from those contemplated. These statements involve risks and uncertainties which may cause actual results, expressed or implied, to differ from predicted outcomes. Risks and uncertainties include product demand, market competition, and Nuvilex’s ability to meet current or future plans. Investors should study and understand all risks before making an investment decision. Readers are recommended not to place undue reliance on forward-looking statements or information. Nuvilex is not obliged to publicly release revisions to any forward-looking statement, to reflect events or circumstances afterward, or to disclose unanticipated occurrences, except as required under applicable laws.
Investor Relations Contact:
Marmel Communications, LLC
Marlin Molinaro, 702-434-8692
KEYWORDS: United States North America Maryland
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Oncology